Melatonin Supplementation Improves Glycemic Control While Lowering Oxidative Stress in Type 2 Diabetes
Year: 2013
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: The purpose of this investigation was to evaluate the effect of melatonin on glycemic control and oxidative stress (OS) in adults with type 2 diabetes (T2D). Fourteen subjects with T2D (10 female, 4 male; 52.5 ± 5.0 years) were randomly assigned to melatonin (MEL) or placebo groups (PLA) for 42 days, in a crossover design. Subjects ingested 10 mg of MEL or an identical placebo (PLA) 30 minutes prior to sleep. Fasting blood draws occurred at baseline, 42 days, and 84 days. Plasma malondialdehyde, a marker of OS, significantly decreased on MEL (-6.25±2.10 nmol/ml) compared to PLA (0.72±3.30, p=0.028). The change in hemoglobin A1c showed a total improvement of 0.33% following MEL supplementation compared to PLA (-0.24±0.23 % for MEL vs. 0.09±0.21 % for PLA, p=0.01), although no significant changes were noted in fasting plasma glucose or lipid levels. Daily melatonin may diminish OS and enhance glycemic control in adults with T2D.
Authors: Carmine R. Grieco, Sheri R. Colberg, C. Thomas Somma, Andrew G.B. Thompson, Aaron I. Vinik
Institution: Glenville State College
Language: English
Subfield: Endocrine and Autonomic Systems
Field: Neuroscience
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W42639007